The prevention or suppression of toxic subclinical epileptiform activity is therefore a useful approach to improve cognition in AD, regardless of disease etiology at the molecular and cellular level, such as Aβ or tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.